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ABSTRACT
Introduction Airway clearance techniques (ACTs) are a 
gold standard of cystic fibrosis management; however, 
the majority of research evidence for their efficacy is of 
low standard; often attributed to the lack of sensitivity 
from outcome measures (OMs) used historically. This 
randomised controlled trial (RCT) investigates these 
standard OMs (sputum weight, forced expiratory volume in 
1 s) and new OMs (electrical impedance tomography (EIT), 
multiple breath washout (MBW) and impulse oscillometry 
(IOS)) to determine the most useful measures of ACT.
Methods and analysis This is a single- centre RCT 
with crossover design. Participants perform MBW, 
IOS and spirometry, and then are randomised to either 
rest or supervised ACT lasting 30–60 min. MBW, IOS 
and spirometry are repeated immediately afterwards. 
EIT and sputum are collected during rest/ACT. On a 
separate day, the OMs are performed with the other 
intervention. Primary endpoint is difference in change 
in OMs before and after ACT/rest. Sample size was 
calculated with 80% power and significance of 5% for 
each OM (target n=64).
Ethics and dissemination Ethics approval was 
gained from the London–Chelsea Research Ethics 
Committee (reference 16/LO/0995, project ID 154635). 
Dissemination will involve scientific conference 
presentation and publication in a peer- reviewed journal.
Trial registration numbers ISRCTN11220163 and 
NCT02721498.
INTRODUCTION
Over 10 500 people in the UK have cystic 
fibrosis (CF),1 a genetic disorder of ion trans-
port across cell membranes causing organ 
damage with a median predicted survival of 
47.3 years. Impaired mucociliary clearance in 
the CF lung due to airway dehydration and 
viscous secretions causes airway obstruction, 
mucus plugging and infections.2 Removal of 
airway secretions is critical to minimise recur-
rent infections and inflammation, which 
lead to lung damage, respiratory failure and 
death.3 4 Traditionally, combinations of muco-
active agents and airway clearance techniques 
(ACTs) are prescribed on an individual basis 
by specialised physiotherapists.5
There are many ACTs including breathing 
methods such as the active cycle of breathing 
techniques (ACBTs) or autogenic drainage 
and adjuncts such as positive expiratory pres-
sure, high frequency chest wall oscillation or 
oscillatory devices, for example, the Acapella. 
Previous research comparing several ACTs 
showed no significant difference in clinical 
effectiveness between techniques over 1 year,6 
and the Association of Chartered Physiother-
apists in Cystic Fibrosis standards of care does 
not advocate one technique over the others 
based on the available evidence.7 However, 
the currently available research regarding 
ACTs is mainly of low quality on the GRADE 
(Grading of Recommendations, Assessment, 
Development and Evaluations) system used in 
systematic reviews,7 often due to methodolog-
ical or outcome measurement issues.
A long- standing debate exists within respi-
ratory physiotherapy and the wider medical 
community about which are the best outcome 
measures (OMs) for research into ACTs in 
CF.8 Established measures of forced expira-
tory volume in 1 s (FEV1) and expectorated 
sputum wet weight have been recognised by 
the international CF community as the gold 
standard for ACT research, although their 
limitations are well recognised.6–12
Spirometry, yielding the FEV1 is effort 
dependent, and is criticised as having high 
variability due to patient participation in the 
manoeuvre.11 The nature of completing a 
forced expiratory manoeuvre, such as FEV1, 
may create an airway reaction or mobilise 
sputum, which on its own, may influence 
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ACT study results. FEV1 also mainly reflects obstruction 
of large airways, and can remain ‘normal’ when signif-
icant small airway damage is present.13 As the small 
airways are affected early in CF lung disease, OMs need to 
effectively monitor this area.14 In addition, studies using 
FEV1 may not detect differences as it may not be sensitive 
enough to pick up small, but possibly clinically significant 
changes.6–8 12
Weight of sputum expectorated is often used as a 
simple OM to reflect the amount of mucus mobilised 
during ACT.7 15 However, sputum expectorated may not 
be the most relevant or valid OM: it is not specific to 
airway clearance or alveolar recruitment; it is not sensi-
tive to small changes or suitable in early disease; and it 
has limited repeatability, being dependent on the will/
ability of a subject to fully expectorate. Sputum could be 
swallowed, cleared after ACT, or contaminated by saliva, 
all which can result in inaccurate estimations of ACT 
effect.7 8 16
Recent technological advances have supported the 
development of new OMs. These may provide more 
detailed information on ACT effect in relation to small 
airways function, ventilation distribution and changes in 
airway obstruction and include multiple breath washout 
(MBW), electrical impedance tomography (EIT) and 
impulse oscillometry (IOS).
The lung clearance index (LCI2.5) is calculated from 
an MBW, which measures the number of lung volume 
turnovers required to clear an inert tracer gas during 
relaxed tidal breathing. When the level of the tracer gas 
has fallen to 1/40th of the starting concentration, the 
washout is considered complete. Functional residual 
capacity (FRC) and the cumulative expired volume 
(CEV) can be derived from MBW measurements, and 
are used to calculate LCI2.5 (CEV divided by FRC).
17 
LCI2.5 reflects ventilation inhomogeneity, increasing with 
airway obstruction typical in more severe disease.18 LCI2.5 
detects small changes in CF lungs, in particular in periph-
eral airways, and so is considered a sensitive measure of 
lung disease severity.18–20 Despite research into reliability, 
validity and responsiveness of LCI2.5 as a longer term 
OM, and support of LCI for clinical trial use by the Euro-
pean CF Society Clinical Trial Network Standardisation 
Committee,14 it is not clear whether LCI2.5 is useful in 
determining differences over a short time, for example, 
single- ACT sessions.14 21 22 In particular, as LCI2.5 is altered 
by airway obstruction, the movement of secretions which 
occurs during ACT, alongside altered ventilation of lung 
segments, could result either in increased or decreased 
LCI2.5; both directions of change have been reported in 
previous small studies measuring ACT effect.22 23
IOS provides information about the mechanical prop-
erties of airways by using alternating frequency pressure 
oscillations, in the form of sound waves, superimposed 
over normal breathing. Airflow and sound wave response 
are used to calculate resistance (R) and reactance (X) 
to tidal breathing.24 Changes in IOS, demonstrating 
changes in resistance to airflow indicate obstructions 
to the airways, for example, mucus plugging or altered 
airway reactivity such as in asthmatic airways.25 Low 
frequency oscillations, such as those at 5 Hz (R5), travel 
through the airways to the peripheries and are reflected 
back, while higher frequencies such as those at 20 Hz 
(R20) are reflected back from central airways.26 Calcu-
lation of the difference between R5 and R20 (R5−R20) 
indicates extent of small airway obstruction. Reactance 
(X) indicates the elastic recoil of the airways. Most liter-
ature is in other patient populations, such as asthma; 
however, there are some studies emerging using IOS as 
an endpoint for CF intervention evaluation.27 28
EIT creates a real- time image of ventilation by measuring 
the impedance to a low voltage electrical current as it 
travels through the lungs. Electrodes are attached to the 
thorax via a belt, and small alternating currents (of a 
magnitude undetectable to the subject) are applied. The 
resulting electrical potentials are measured, and a recon-
struction algorithm is used to obtain the electrical imped-
ance distribution within the thorax.29 Analysis of the data 
obtained calculates end expiratory lung impedance, 
which is affected by changes in lung volumes and venti-
lation, and so has been proposed as a measure to detect 
changes resulting from sputum mobilisation and ACT.6 30 
Most current literature in EIT is from the intensive care 
environment,29 31 with few studies investigating EIT in 
CF.32–34 Wettstein et al34 demonstrated that EIT detected 
differences in ventilation distribution following ACT in 
a small cohort of nine CF adults, but reported high vari-
ability. These findings support further investigation of a 
larger sample of patients during ACT with a wide range 
of lung disease severity to assess whether the high inter-
subject variability observed is due to differences within 
the individual participants (eg, airway obstruction), or 
due to the inherent variability of EIT itself.
The importance of patient preference and patient 
reported OMs (PROMs) is acknowledged within CF 
ACT research.8 9 12 The most sensitive OM scientifically, 
may be the least useful clinically if patients do not wish 
to perform it. The present study, therefore, includes a 
PROM in the form of a questionnaire asking opinions on 
the OMs performed. Good patient feedback of an OM is 
the key to its future within CF research and clinical care.
Several Cochrane reviews suggest further work is 
required to identify the most appropriate OMs for ACT 
assessment.8 15 35–40 The European CF Society Allied 
Health and Nursing Professions Working Group reported 
the need for evaluation and identification of appropriate 
and robust OMs for allied health professional research as 
one of their four key objectives.41
This study seeks to identify a robust OM in ACT 
research that will benefit patients, facilitating their choice 
of ACT. Additionally, identifying the best OM will benefit 
the physiotherapy community in designing future trials 
of ACTs. Furthermore, industry can use this research in 
the assessment of new devices and mucoactive agents.
Our hypothesis is that the use of a new OM tool box 
will allow more sensitive assessment of ACTs in stable 
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adult patients with CF than the current gold standard 
measures. It was developed following extensive litera-
ture review and discussions with CF experts and patients. 
These experts acknowledge that physiotherapy prac-
tice guidelines are largely based on low- grade evidence 
because of underpowered studies with poor OMs.7 42 This 
study seeks to improve this situation by evaluating new 
OMs thoroughly, providing robust evidence, which could 
then be used in future studies.
METHODS AND ANALYSIS
Trial registration
This trial is registered on the public database www. clini-
caltrials. gov. uk and is part of the International Standard 
Randomised Controlled Trial Number (ISRCTN) data-
base.
Patient involvement
Patients were involved in the conceptualisation, design 
and conduct of this research. During planning patients’ 
opinions on the trial design, research question and 
recruitment methods were gathered via discussions with 
adults with CF, and the Patient Representatives Group 
(RPG) of the Respiratory Clinical Research Facility 
(RCRF) based at the Royal Brompton Hospital (RBH), 
London. The study assessment questionnaires (online 
supplemental appendices 1 and 2) have been designed 
and developed in conjunction with the CF patient advo-
cate at RBH and the RPG. A patient representative is an 
independent member of the trial steering committee.
Study design
This is an open label, single- centre, single- blind, 
randomised controlled crossover trial investigating OMs 
for ACT in stable adults with CF. Figure 1 illustrates the 
study design.
Recruitment
Adults (16+ years) with CF registered as RBH patients are 
eligible for inclusion. Patients are approached during 
routine clinic visits for a project introduction and are 
given a patient information sheet (PIS) (first recruitment 
contact). They are given at least 48 hours to consider the 
PIS before a follow- up communication is completed to 
discuss any questions regarding study involvement and to 
arrange their first study visit if applicable.
Inclusion/exclusion criteria
The study’s inclusion and exclusion criteria are listed 
in table 1. In addition, before the start of any planned 
study visit (visit 1 or 2), participants are screened through 
discussion with the research team to see if they are unwell 
or if they have had any treatment changes to their CF or 
CF- related conditions within 4 weeks of the visit date. If 
treatment changes have occurred or the person is unwell, 
the visit is postponed.
Informed consent
Every potential participant is provided with a PIS, verbal 
study explanation and the opportunity to ask questions 
regarding participation at the first recruitment contact. 
Following this, each participant is given a full explana-
tion of what the study entails at the start of visit 1, and has 
the opportunity to ask questions before the consent form 
is provided. Written informed consent for participation is 
gained at start of visit 1, and verbally confirmed at visit 2.
Study visits
Study visits are booked in advance with the participant’s 
agreement and consist of two separate visits to the RBH 
RCRF, ideally occurring within 3 months of each other. 
Participants complete their usual morning routines 
before visit attendance, which may include nebulisers 
Figure 1 Schematic of trial design. Diagram illustrating the research journey for a trial participant, from their recruitment 
and giving of informed consent to completing study day one: baseline outcome measures (OMs) followed by randomisation 
to intervention (rest or airway clearance therapy (ACT)) and postintervention OMs. The time gap in- between visits should be 
no longer than 3 months. On study day 2, the participant completes the same OMs before and after the other intervention. 
Participation in the study is then complete.
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and ACT, and are specifically asked to ensure they 
complete exactly the same routine before the second 
research visit.
Prior to starting study assessments, subjects are ques-
tioned to ensure they are in a stable state of their disease 
and continue to satisfy the inclusion and exclusion 
criteria. To ensure stability in disease state in between the 
2 assessment days, spirometric measurements of FEV1 and 
FVC are required to be within 5% absolute percentage 
points of the recorded prevalues at visit 1 when taken at 
visit 2.
The format of a trial visit is shown in figure 2. Subjects 
perform MBW, IOS and spirometry, then a 2 min EIT 
recording is performed. The EIT belt stays in situ 
throughout the intervention period (ACT or rest) that 
is supervised by a specialist CF physiotherapist. Coughs, 
expectoration frequency and oxygen saturations are 
recorded during the intervention period and a 2 min EIT 
recording is completed. At the end of the intervention 
period, the participant completes a Likert scale ques-
tionnaire asking how the intervention completed has 
affected their breathing and sputum clearance (online 
supplemental appendix 1). At the end of the interven-
tion period, a further 2 min EIT recording is completed 
before removing the EIT belt. MBW, IOS and spirometry 
are repeated immediately after the intervention period. 
Patient views on the OMs in terms of comfort, ease to 
perform and preference are gathered via a second ques-
tionnaire at the end of each study visit (online supple-
mental appendix 2).
Interventions
Intervention 1: airway clearance
The ACBTs have been selected as the ACT within this 
study as it was the most common non- equipment- reliant 
ACT performed in the UK at the time of trial set- up,43 
and is easy to learn. All participants complete ACBT as 
the ACT intervention to prevent complications of anal-
ysis from possible differing effects of different ACTs. 
ACBT includes three elements—breathing control, 
thoracic expansion exercises and the forced expiration 
technique (also known as a ‘Huff’) (figure 3).44 Teaching 
or revision of ACBT from a specialist CF physiotherapist 
is provided at the start of both trial visits to ensure correct 
technique. The participant completes ACBT cycles in a 
supported sitting position. Supervision from a specialist 
CF physiotherapist is provided during the intervention 
session to encourage good ACBT and patient motivation.
Intervention 2: rest
In the second intervention period, the participant rests in 
a seated position (the same position as ACT is completed 
in). This intervention acts as the control arm for the 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Diagnosis of cystic fibrosis 
as confirmed by standard 
criteria52
Evidence of pulmonary 
exacerbation within 3 weeks 
prior to screening
Sixteen years of age or 
older
Any change in a chronic 
treatment/prophylaxis for CF or 
CF- related condition within 4 
weeks of visit
Current haemoptysis
Dependency on positive 
pressure support with airway 
clearance technique
Previous history of spontaneous 
rib fracture
Pregnancy
Inability to give consent for 
treatment or measurement
Enrolment in another 
interventional study
Dependent on non- invasive 
ventilation or oxygen therapy 
at rest
Figure 2 Flow diagram of a study visit. CF, cystic fibrosis, 
EIT, electrical impedance tomography; ISO, impulse 
oscillometry; MBW, multiple breath washout.
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study. Supervision is provided to ensure the participant 
does rest.
Participants are their own controls and are randomly 
assigned to the order that they perform the study sessions 
by a computerised randomisation programme. The 
randomisation code is held by the principle investigator 
who is not involved with study visits. One visit involves 
a period of rest for 30 min in- between assessments; 
the other visit involves a session of ACT using ACBT 
(figure 1). The length of the ACT and rest intervention 
periods are the same, and are predetermined prior to the 
first visit based on the length of the participant’s usual 
ACT routine. Sessions last for a minimum of 30 min, up 
to 60 min maximum.
To minimise bias, all OMs are completed by the same 
investigator as far as possible; they are blinded to the 
order of the study visits and are not present during the 
intervention period. Both the intervention periods are 
supervised by the specialist CF physiotherapist. The 
specialist CF physiotherapist and the participant are 
instructed to not divulge which intervention has been 
completed to the investigator or to any other party. The 
questionnaire asking how the participant feels after the 
intervention (online supplemental appendix 1) is given 
by the specialist physiotherapist and is returned to the 
investigator in a sealed envelope to be opened at the end 
of the data collection period for all subjects.
Study OMs
A summary of OM procedures is stated in table 2.
Multiple breath washout
The MBW test is completed following the standard oper-
ating procedure for the Exhalyzer D machine (EcoMe-
dics AG, Switzerland).45 Calibration for environmental 
conditions, flow and volume is completed prior to test 
completion. Disposable antibacterial filters and sterile 
mouthpieces are used. Distraction is provided during 
the test via a television programme. The MBW test is 
completed when three acceptable measurements are 
obtained. Once the tests are completed, the data are 
downloaded and analysed using Spiroware V.3.1 (EcoMe-
dics AG, Switzerland).
Impulse oscillometry
Calibration for ambient conditions, volume and imped-
ance reference is performed before each use. The 
IOS tests are completed in an upright seated position, 
following a standard RBH hospital protocol which was 
described by Paredi et al.24 Disposable antibacterial filters 
and sterile mouthpieces are used. The patient is asked to 
place their hands over their cheeks to prevent wobble and 
a nose clip is worn. The patient is instructed to breathe 
normally on the mouthpiece and at least 30 s of ‘normal 
breathing’ is completed before the test is commenced. 
Once started, the patient continues to breathe normally 
for a further 30 s, which is recorded. Each test is reviewed 
after completion and abnormal breaths (eg, coughs or 
swallows) excluded from the final analysis. The test is 
repeated when three acceptable measurements have 
been completed.
Spirometry
Spirometry is completed using a MicroLab spirom-
eter (Carefusion, UK) and following the European 
Figure 3 The active cycle of breathing techniques 
(adapted from the International Physiotherapy Group- Cystic 
Fibrosis (IPG/CF) Blue Booklet, 201944).
Table 2 Details of outcome measures
Outcome measure test
Equipment used
(manufacturer) Guideline or protocol followed
Spirometry MicroLab hand held spirometer (Carefusion 
UK, Basingstoke, UK)
Joint European Respiratory Society/
American Thoracic Society guidelines11
Impulse oscillometry (IOS) Jaeger IOS (Jaeger, Wurzburg, Germany) Royal Brompton and Harefield NHS 
Foundation Trust standard operating 
procedure described by Paredi et al24
Multiple breath nitrogen washout Ecomedics Exhalyzer D machine (Eco 
Medics AG, Duernten, Switzerland)
Ecomedics Exhalyzer D standard operating 
procedure.45
Electronic impedance tomography Draeger Pulmovista 500 (Draeger Medical 
U.K. Limited, Hemel Hempstead, UK)
Pulmovista 500 operator guidance (Draeger 
Medical, Germany)
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Respiratory Society/American Thoracic Society guide-
lines.11 Disposable antibacterial filter mouthpieces are 
used for each patient. Each test is repeated three times 
and the best value was recorded. Percentage predicted 
values are obtained using the Global Lung Initiative 2012 
equations.46 Calibration of the equipment is performed 
before each use.
Electrical impedance tomography
EIT recordings are made via electrodes connected to a 
thoracic belt, which is then connected via a trunk cable to 
the Pulmovista 500 machine (Draeger Medical UK, UK). 
Belt size is determined using a guide measure (Draeger 
Medical UK, UK). The belt is placed around the chest as 
per the manufacturer’s guidance (instructions for use—
Pulmovista 500, Draeger, UK) at the height of the 4th–6th 
intercostal space with the belt moistened using water for 
enhanced contact. A reference electrode is attached to 
the seated patient using a disposable adhesive ECG elec-
trode (Leonhard Lang GmbH, Austria). System checks 
and signal quality are checked prior to the first recording 
as per the manufacturer’s guidelines. Recordings are 
completed, before and after the intervention period 
and one in the middle of the intervention period; each 
recording is 2 min in duration. Recordings are uploaded 
to the EIT Data Analysis Tool (Draeger Medical UK, UK). 
Further analysis is then completed using Excel.
Oxygen saturations
Oxygen saturations are monitored continuously 
throughout the intervention periods using a Pulsox- 
300i oximeter and finger probe (Stowood Medical, UK). 
Recordings are analysed using Visi- Download software 
(Stowood Scientific Instruments, UK).
Sputum collection
Patients are given a sputum pot with lid (Unisurge, UK) 
to expectorate into throughout the intervention period. 
The pot is weighed pre and post use using portable scales 
(Kenex, UK).
End of trial and follow-up
There are no follow- up contacts for participants after 
completion of visit 2. The trial will end once 64 partic-
ipants have been recruited, and have completed both 
study visits.
Primary and secondary outcomes
As this study assesses the five OMs with equal weight, the 
main measurement derived from each of the OM tests 
are all considered to be primary outcomes (table 3), 
and were all considered in the calculations to derive 
the optimal sample size. Other measurements that can 
be derived from each of the OMs will be investigated as 
secondary outcomes.
Sample size calculations
In this study, we are assessing changes in OMs before and 
after ACT. To do this, for each individual participant we 
are calculating the change in the OM before and after 
ACT and comparing this with the change in the same 
OM after a period of rest. Due to the lack of agreement 
and definition as to what a minimal clinical important 
difference is for most of these OMs within the CF popu-
lation,47 48 we conducted sample size calculations based 
on detecting minimum clinically relevant differences 
(MCRDs) from expert opinion and previous research 
findings.30 34 Sample size calculations were based on 
detecting MRCDs with 80% power and a significance 
level of 5% for all five OMs and on the premise of using a 
two- sample paired means test. All sample size calculations 
were conducted in STATA V.13.
From the calculations, FEV1 required the largest sample 
size of 32 participants. Initially we planned to study 
patients based on three severities of lung disease by FEV1 
(mild (>70% FEV1 predicted), moderate (40%–70% FEV1 
predicted) and severe (<40% FEV1 predicted)); therefore, 
we aimed to recruit 32 patients in each group. Allowing 
for drop outs, we aimed to recruit a total of 106 partici-
pants. However, due to difficulties recruiting participants 
with low lung function, the protocol was changed (with 
Research Ethics Committee (REC) approval in March 
Table 3 Primary and secondary outcome measures
Primary outcome measures Secondary outcome measures
 ► Forced expiratory volume in 1 s
 ► Sputum wet weight expectorated during treatment
 ► End expiratory lung impedance derived from EIT
 ► LCI2.5 derived from MBW
 ► R5–R20 derived from IOS
 ► Forced vital capacity (FVC), forced expiratory flow at 25% of 
FVC, forced expiratory flow at 50% of FVC, forced expiratory 
flow at 75% of FVC, slow vital capacity derived from 
spirometry
 ► Oxygen saturation measurements during treatment
 ► Patient feedback questionnaire
 ► Regions of interest % derived from EIT
 ► Functional residual capacity, LCI5, Scond, Sacin, washout time, 
number of washout breaths, M1M0, M2M0 derived from MBW
 ► R5, R20, X, Fres derived from IOS
EIT, electrical impedance tomography; IOS, impulse oscillometry; LCI 2.5, Lung Clearance Index; MBW, multiple breath washout.
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2020) to study two groups (FEV1 over 60% and FEV1 60% 
or below), requiring 70 participants.
Data analysis plan
Demographic and outcome numerical data will be 
summarised as mean (SD) or median (IQR) depending 
on the distribution of the data and categorical data will 
be presented with frequencies (percentage).
Between visit differences in the change in OM’s will be 
compared using the paired t test or the Wilcoxon sign- 
ranked test as appropriate. All tests will be two- sided and 
significance will be set at p<0.05.
The clinimetric properties of the OMs will be assessed 
and minimally important changes (MICs) to partici-
pants will be calculated.49 Construct validity as a measure 
of responsiveness will be assessed using a construct 
approach. Reliability will be assessed by calculating intra-
class correlation coefficients and limits of agreement 
using Bland and Altman plots, taking measurement error 
between study days into account.
MICs differ from MCRDs, because MICs are calculated 
from patient feedback, and so represent what needs to 
change in an OM for a patient to feel a difference,49 
as opposed to an MCRD, which is defined by clinical 
experts.50 MICs will be calculated using an anchor- based 
method49–51 derived from the results of the intervention 
effect questionnaire (online supplemental appendix 1).
The clinimetric properties of the secondary OMS will be 
explored using the same approach. Exploratory analysis of 
associations between the OMS and change in OMs will be 
completed.
To ensure blinding of investigators, no interim anal-
ysis is planned. Data analysis will be completed once full 
recruitment is accomplished and data gathered.
ETHICS AND DISSEMINATION
Ethics approval was gained for this trial from the London–
Chelsea REC on 5 August 2016, with Health Research 
Authority (HRA) approval granted on 31 August 2016 
(reference 16/LO/0995) and local research and develop-
ment approval on 7 September 2016.
Safety reporting
Data on serious adverse events (SAE: as described by good 
clinical practice guidelines) and adverse events (AEs) will 
be collected during the trial visits and during time gaps 
in- between visits. All SAEs will be reported to the sponsor 
within 48 hours of notification, and will be followed until 
resolution. SAEs in this study include participant hospital-
isation, including elective admissions, for any condition 
including pre- existing conditions. There are no expected 
AEs for this trial, except for possible fatigue from comple-
tion of interventions, and so all AEs are treated as unex-
pected, discussed with the trial management team, then 
reported to the sponsor in the annual progress report.
Changes to trial after commencement
The study details reported here are described within the trial 
protocol V.4.2 (date: 20 January 2020). There have been two 
protocol amendments, the first of which added the interven-
tion effect questionnaire into the trial visits (online supple-
mental appendix 1). The first amendment was granted 
ethical approval by the London–Chelsea REC on 16 March 
2017 and HRA approval on 27 March 2017. The second 
protocol amendment changed from studying three groups 
of participants by level of FEV1 (FEV1 mild (over 70% FEV1 
predicted), moderate (40%–70% FEV1 predicted) and 
severe (under 40% FEV1 predicted)), to studying two groups 
(FEV1 over 60% and FEV1 60% or below) due to recruitment 
difficulties in the severe lung function group. The second 
amendment also included the addition of slow vital capacity 
into the protocol as a secondary OM. The second trial 
amendment was granted ethical approval by the London–
Chelsea REC and the HRA in March 2020.
Publication and dissemination
All participants will receive a lay summary of results 
on study completion. Trial results will be presented at 
national and international conferences, and local scien-
tific meetings of Imperial College, London, and RBH. 
A report on results will be submitted to the trial funder 
(National Institute for Health Research). Publication will 
be pursued in a relevant peer- reviewed scientific journal.
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